Related Experiment Video
Updated: Jun 17, 2026
11:58
Primary Culture of Mouse Dopaminergic Neurons
Published on: September 8, 2014
The cholinergic system and Parkinson disease.
Nicolaas I Bohnen1, Roger L Albin
1Department of Radiology, University of Michigan, Ann Arbor, MI, USA. nbohnen@umich.edu
Behavioural Brain Research
|January 12, 2010
Summary
Parkinson disease (PD) involves more than motor symptoms. Cholinergic system degeneration contributes to cognitive decline and non-motor issues like impaired smell and balance in PD patients.
Area of Science:
- Neuroscience
- Neurology
- Pathology
Background:
- Parkinson disease (PD) is traditionally linked to motor deficits from dopaminergic neuron loss.
- Emerging evidence highlights significant non-motor features in PD, including cognitive impairment.
- These non-motor symptoms suggest complex multi-system degeneration beyond the nigrostriatal pathway.
Purpose of the Study:
- To investigate the role of cholinergic system degeneration in Parkinson disease.
- To correlate cholinergic deficits with non-motor symptoms, particularly cognitive impairment, in PD.
- To explore the association between cholinergic denervation and specific PD phenotypes.
Main Methods:
- Review of in vivo neuroimaging studies on cerebral cholinergic markers in PD.
- Analysis of post-mortem evidence of basal forebrain cholinergic system degeneration.
- Correlation of cholinergic denervation patterns with cognitive status and other non-motor symptoms.
Main Results:
- In vivo imaging shows significant loss of cerebral cholinergic markers in parkinsonian dementia, comparable to Alzheimer disease.
- Basal forebrain cholinergic system degeneration is an early feature in PD, worsening with dementia.
- Cholinergic denervation in PD is heterogeneous and linked to cognitive deficits, olfactory impairment, and gait disturbances.
Conclusions:
- Cholinergic system degeneration is a critical pathological feature in Parkinson disease, contributing significantly to cognitive impairment.
- Early and progressive cholinergic deficits impact various non-motor symptoms in PD.
- Targeting the cholinergic system may offer therapeutic avenues for non-motor aspects of Parkinson disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...